Jeffrey B. Mirviss - Jan 1, 2025 Form 4 Insider Report for BOSTON SCIENTIFIC CORP (BSX)

Role
EVP&Pres, Periph Intervent
Signature
/s/ Susan Thompson, Attorney-in-Fact
Stock symbol
BSX
Transactions as of
Jan 1, 2025
Transactions value $
-$935,449
Form type
4
Date filed
1/3/2025, 04:32 PM
Previous filing
May 30, 2024
Next filing
Feb 13, 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BSX Common Stock Options Exercise $0 +10.4K +36.66% $0.00 38.9K Jan 1, 2025 Direct F1, F2
transaction BSX Common Stock Tax liability -$293K -3.28K -8.43% $89.32 35.6K Jan 1, 2025 Direct
transaction BSX Common Stock Sale -$643K -7.15K -20.09% $89.86 28.5K Jan 3, 2025 Direct F3, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BSX Performance Share Units Options Exercise $0 -10.4K -100% $0.00 0 Jan 1, 2025 Common Stock 10.4K Direct F1, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 On February 10, 2022, the reporting person was awarded a target number of performance share units under the Company's 2022 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2022 adjusted free cash flow measured against its 2022 financial plan over the one-year performance period ending December 31, 2022 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 14, 2023, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined vested in whole upon the completion of the individual service period that ended on December 31, 2024.
F2 Includes shares acquired on June 30, 2024 under the Company's Employee Stock Purchase Plan based upon the most current data available.
F3 The transaction reported in this Form 4 was effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on February 28, 2024.
F4 Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $89.523 to $90.15, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
F5 Each performance shares unit represents the Company's commitment to issue one share of Boston Scientific common stock.